MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

NCT03004105 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Inadequate funding

Conditions

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
Advanced Lung Cancer
Recurrent Nonsmall Cell Lung Cancer

Interventions

DRUG: Selumetinib
DRUG: Durvalumab
BEHAVIORAL: Phone Calls

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]